Company: DRTSW
Filing Date: 2025-04-28
Form Type: 6-K
Source: 0001213900-25-035812
Chunk: 1

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 6-K
Chunk 1
---
 to the Registration Statement on Form
F-3 (File No. 333-271073) (the “Registration Statement”), including the base prospectus contained therein and a prospectus
supplement related to the Offering. The Registration Statement was filed by the Company with the Securities and Exchange Commission (the
“Commission”) on April 3, 2023, and was declared effective by the Commission on April 13, 2023.

The foregoing summary of the Purchase Agreement does not purport to
be complete and is subject to, and qualified in their entirety by, the copy of such document attached as Exhibit 10.1 to this Report on
Form 6-K (this “Report”), which is incorporated herein by reference.

This Report shall not constitute an offer to sell any securities or
a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state
or jurisdiction.

A copy of the opinion of Meitar | Law Offices relating to the legality
of the issuance and sale of the Shares, including the consent included therein, is attached as Exhibit 5.1 to this Report.

On April 28, 2025, the Company issued a press release announcing the
closing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated by reference into this Report.

<div align='center'>1</div>

Strategic IR/PR Services Agreement

On April 24, 2025, concurrent with the execution of the Purchase Agreement,
the Company entered into a Strategic IR/PR Services Agreement (the “Strategic Services Agreement”) with Oramed Ltd. (the “Investor”
or “Oramed”), whereby the Company engaged Oramed, on a non-exclusive basis, to provide it with comprehensive strategic Investor
Relations and Public Relations management services in territories including the United States, Israel and South Korea.

As consideration for the services under the Strategic Services Agreement,
the Company agreed to pay to Oramed a non-refundable fee of $3,000,000, with $500,000 payable upon execution of the Strategic Services
Agreement and the remaining $2,500,000 payable in five (5) equal installments every six (6) months following the date of the Strategic
Services Agreement.

In addition, subject to the approval